Translational Research
Volume 156, Issue 2 , Pages 98-105 , August 2010

Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer

  • Tomoya Yokota

      Affiliations

    • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    • Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    • ,
  • Noriko Shibata

      Affiliations

    • Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    • ,
  • Takashi Ura

      Affiliations

    • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    • ,
  • Daisuke Takahari

      Affiliations

    • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    • ,
  • Kohei Shitara

      Affiliations

    • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    • ,
  • Kei Muro

      Affiliations

    • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
    • ,
  • Yasushi Yatabe

      Affiliations

    • Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    • Corresponding Author InformationReprint requests: Yasushi Yatabe, Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan

Received 31 March 2010 ,Revised 22 May 2010 ,Accepted 25 May 2010.

References 

  1. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003;30:3–14
  2. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol. 2002;29:3–9
  3. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208
  4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  5. Jonker DJ, Karapetis CS, Moore M, et al. Randomized Phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). Proceedings of the American Association for Cancer Research Annual Meeting, 2007.
  6. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803–1810
  7. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med. 2004;351:2883
  8. Kinzler KW, Vogelstein B. Colorectal tumors. In:  Kinzler KW,  Vogelstein B editor. The genetic basis of human cancer. London, UK: McGraw-Hill; 1999;p. 565–587
  9. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855–867
  10. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol. 2008;26
  11. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol. 2008;26
  12. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765
  13. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705–5712
  14. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643–2648
  15. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer. 2009;101:465–472
  16. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn. 2006;8:335–341
  17. Sakamoto H, Shimizu J, Horio Y, et al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol. 2007;212:287–294
  18. COSMIC (Catalogue of somatic mutations in cancer) database. Available at: http://www.sanger.ac.uk/genetics/CGP/cosmic/.
  19. Mancl EE, Kolesar JM, Vermeulen LC. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. Am J Health Syst Pharm. 2009;66:2105–2112
  20. Williams C, Pontén F, Moberg C, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol. 1999;155:1467–1471
  21. William Pao, Marc Ladanyi. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res. 2007;13:4954–4955
  22. Nagahara H, Mimori K, Ohta M, et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res. 2005;11:1368–1371
  23. Tsao M-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–144
  24. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med. 2006;354:526–528
  25. Akbari M, Hansen MD, Halgunset J, Skorpen F, Krokan HE. Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. J Mol Diagn. 2005;7:36–39

PII: S1931-5244(10)00100-3

doi: 10.1016/j.trsl.2010.05.007

Translational Research
Volume 156, Issue 2 , Pages 98-105 , August 2010

Article Tools

* Image Usage & Resolution